Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1997-04-16
2001-07-03
Achutamurthy, Ponnathapu (Department: 1652)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023500, C530S350000
Reexamination Certificate
active
06255464
ABSTRACT:
BACKGROUND OF THE INVENTION
Neoplasia involves the clonal expansion of cells which can escape the inhibitory influences that normally limit cell growth. The revolution in cancer research that has occurred over the last decade has largely involved the discovery of genes which confer these inhibitory influences and the delineation of mutations of these genes in various tumour types. TGF-&bgr; is one of the cytokines that can inhibit epithelial cell growth, and has been extensively studied for over a decade (1-5). Resistance to TGF-&bgr; is common in human cancers of many types, emphasizing the importance of this secreted polypeptide to the neoplastic process (6). However, the mechanisms by which tumour cells become resistant to TGF-&bgr; are generally unknown.
Much has been learned about TGF-&bgr;, its receptors, and its physiologic effects. TGF-&bgr; is now known to be the prototype for a large and conserved family of related polypeptides which have diverse physiologic functions in organisms as disparate as Drosophila,
C. elegans,
and
Homo
sapiens. The TGF-&bgr; signal is initially received by a receptor complex containing the products of three different genes (TGF-&bgr; receptor types RI, RII, and RII). This signal is apparently mediated by the serine/threonine kinase activities of RI and RII. Though a small number of potential substrates for these receptor kinases have been identified (7-11) the biochemical pathways that are stimulated by these kinase activities are largely unknown. However, genes which appear to function downstream of these receptors, on the basis of genetic criteria, have been identified in Drosophila and
C. elegans.
Mutations of the
C. elegans
genes sma-2, sma-3, and sma-4 confer phenotypic abnormalities identical to those observed with mutants of a TGF-&bgr;-family receptor gene (daf-4) in this organism (12). Savage et al. have proposed the name “dwarfins” for the corresponding proteins, homologues of which have been identified in the human (12). Similarly, mutations in the Drosophila Mad gene result in phenotypes like those observed in strains with mutations of the TGF-&bgr;-like ligand dpp (13,14). The Mad and sma genes are highly related by sequence, suggesting they all function similarly as mediators of TGF-&bgr;-like signaling (13,14). The Mad and sma genes have no relationship to other known signaling molecules, and encode no motifs that provide clues to their biochemical function. It is likely, however, that the final arbiters of the growth inhibition conferred by TGF-&bgr; family members include the cyclin-dependent kinase inhibitors (15).
The importance of the TGF-&bgr; pathway to colorectal tumorigenesis has recently been highlighted by two observations. A subset of colorectal tumors has been shown to harbor inactivating mutations of the TGF-&bgr; RII gene (16,17). This subset, accounting for about 15% of total colorectal cancers (18-20), comprises tumours with characteristic defects in mismatch repair (21), and the high frequency of TGF-&bgr; RII gene mutations in this tumour type results from a mutation-prone polyadenosine tract within the coding region of the gene. Though most other colorectal cancers have been shown to be resistant to the inhibitory effects of TGF-&bgr; (2,6), the cause of such insensitivity is unknown. Mutations of the TGF-&bgr; RII gene or of the cdk inhibitor genes p15, p16, and p21 are not generally found in these tumours (22,23), suggesting that the defects lie in the intermediates in the signaling pathway. This hypothesis recently received experimental support with the discovery of the DPC4 gene (24). DPC4 was identified through a positional cloning approach designed to identify a pancreatic tumour suppressor gene on chromosome 18q21. The DPC4 gene was found to be highly related to Mad and sma and genetic alterations which affected DPC4 were observed in over 50% of pancreatic cancers. Analogous studies of other human cancers, including those of the colon, revealed that DPC4 was genetically altered in only a minority of cases (25,26). There is a need in the art for identification of additional human genes homologous to DPC4 and its lower eukaryotic homologues (hereinafter referred to as the Mad gene family) which are involved in neoplastic processes.
SUMMARY OF THE INVENTION
It is an object of the invention to provide a cDNA of the human Smad2 gene.
It is another object of the invention to provide an isolated Smad2 human protein.
It is yet another object of the invention to provide a pair of primers for amplification of the Smad2 gene.
It is still another object of the invention to provide probe for detecting Smad2 coding sequences.
It is an object of the invention to provide a preparation of antibodies which specifically binds a human Smad2 protein.
It is another object of the invention to provide methods for screening test substances for the ability to suppress neoplasia.
It is still another object of the invention to provide an animal which carries in its genome a mutation in the Smad2 gene.
It is yet another object of the invention to provide methods to aid in diagnosing or prognosing neoplasias.
It is a further object of the invention to provide methods of supplying wild-type Smad2 gene function to a cell which has lost Smad2 gene function.
It is another object of the invention to provide methods of supplying wild-type Smad2 gene function to a cell which has altered Smad2 gene function.
It is still another object of the invention to provide a method of detecting neoplastic tissue.
It is a further object of the invention to provide a method for detecting genetic predisposition to cancer.
It is another object of the invention to provide a cDNA of a human Smad gene.
It is yet another object of the invention to provide an isolated human Smad protein.
These and other objects of the invention are provided by one or more of the embodiments disclosed below. In one embodiment, an isolated cDNA of the human Smad2 gene is provided.
In another embodiment of the invention an isolated human Smad2 protein is provided.
In yet another embodiment of the invention a pair of primers for amplifying Smad2 coding sequences is provided. The first primer of said pair comprises at least 12 contiguous nucleotides selected from SEQ ID NO:1 and the second primer of said pair comprises at least 12 contiguous nucleotides selected from the complement of SEQ ID NO:1.
In still another embodiment of the invention a probe for detecting Smad2 coding sequences is provided. The probe comprises an oligonucleotide consisting of at least 12 contiguous nucleotides selected from SEQ ID NO:1 or the complement thereof.
In another embodiment of the invention a preparation of antibodies is provided. The preparation of antibodies specifically binds human Smad2 protein. The antibodies are not substantially immunoreactive with other human proteins.
In one embodiment of the invention a method of screening test substances for the ability to suppress a neoplastically transformed phenotype is provided. A test substance is applied to a cell which carries a mutation in the Smad2 gene. The ability of the test substance to suppress the neoplastically transformed phenotype is then determined.
In another embodiment of the invention another method of screening test substances for the ability to suppress neoplastic growth is provided. A test substance is administered to an animal which carries a mutant Smad2 gene. The ability of the test substance to prevent or suppress the growth of tumors is then determined.
In still another embodiment of the invention an animal which carries in its genome a mutant Smad2 gene is provided.
In yet another embodiment of the invention an animal which has been genetically engineered to contain in its genome an insertion mutation which disrupts the Smad2 gene is provided.
In a further embodiment of the invention a method of aiding in the diagnosis or prognosis of a neoplastic tissue of a human is provided. Alteration of wild-type coding sequences of the Smad2 gene are detected in a tumor tissue isolated from a human. The alteration indica
Kinzler Kenneth W.
Riggins Gregory R.
Thiagalingam Sam
Vogelstein Bert
Achutamurthy Ponnathapu
Banner & Witcoff Ltd
The Johns Hopkins University
Tung Peter P.
LandOfFree
Mad-related genes in the human does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mad-related genes in the human, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mad-related genes in the human will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2487490